fda glp-1 warning 2025 november Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines With FDA approval of Wegovy

74% of people who quit a GLP-1 plan to restart within a year (NPR, 2026)

Fatty liver: Can lead to fatty liver disease, which may progress to liver dysfunction, cirrhosis, or require liver transplant

Diarrhea on GLP-1 medications: rates by drug, why it happens, how long it lasts, foods and fixes that help, loperamide safety, and when to call a provider.

When oxidative demand approaches the regenerative capacity of nicotinamide adenine dinucleotide (NAD)/ nicotinamide adenine dinucleotide phosphate (NADPH

Explore 3 new drugs for chronic conditions including obesity, severe asthma and hives (also known as urticaria).

Systematic summarization of MBSH criteria allowed us to identify the predictors for MBSH, which can aid in early diagnosis and treatment, reducing the need for prolonged monitoring.